Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

Saved in:
Bibliographic Details
Title: Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
Authors: Fu DJ; Clinical Development, Janssen Scientific Affairs, 1125 Trenton-Harbourton Rd, Titusville, NJ 08560 dfu@its.jnj.com., Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L
Source: The Journal of clinical psychiatry [J Clin Psychiatry] 2015 Mar; Vol. 76 (3), pp. 253-62.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Physicians Postgraduate Press Country of Publication: United States NLM ID: 7801243 Publication Model: Print Cited Medium: Internet ISSN: 1555-2101 (Electronic) Linking ISSN: 01606689 NLM ISO Abbreviation: J Clin Psychiatry Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1555-2101
DOI:10.4088/JCP.14m09416